Table 3.
Univariable and multivariable Cox regression analyses for time to OS before and after PSM analysis.
| Characteristics | Before PSM Univariable analysis |
Multivariable analysis | After PSM Univariable analysis |
Multivariable analysis | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) value |
P | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) |
P
value |
|
| therapy options | 0.001 | 0.001 | 0.002 | 0.002 | ||||
| SI+HAIC+Len+P | reference | reference | reference | reference | ||||
| SI+HAIC+Len | 2.025(1.143-3.055) | 2.025(1.143-3.055) | 2.684(1.436-5.019) | 2.684(1.436-5.019) | ||||
| Age (years) | 1.014(0.982-1.048) | 0.389 | 0.970(0.920-1.023) | 0.263 | ||||
| Sex | 0.383 | 0.233 | ||||||
| Male | reference | reference | ||||||
| Female | 0.760(0.410-1.408) | 0.603(0.263-1.384) | ||||||
| Etiology | 0.958 | 0.940 | ||||||
| Hepatitis B | 1.018(0.516-2.011) | 1.164(0.368-2.525) | ||||||
| Others | reference | reference | ||||||
| Child Pugh score | 0.862 | 0.890 | ||||||
| 5-6 | 0.950(0.535-1.687) | 0.960(0.465-2.419) | ||||||
| 7-9 | reference | reference | ||||||
| Tumor subtype | 0.058 | 0.280 | ||||||
| Perihilar cholangiocacinoma | reference | reference | ||||||
| Distal cholangiocacinoma | 0.681(0.457-1.014) | 0.863(0.574-1.243) | ||||||
| Differentiated histology | 0.955 | 0.924 | ||||||
| poorly | reference | reference | ||||||
| others | 0.989(0.677-1.446) | 0.975(0.577-1.647) | ||||||
| TNM stage | 0.480 | 0.479 | ||||||
| III | reference | reference | ||||||
| IV | 1.234(0.689-2.211) | 1.347(0.591-3.072) | ||||||
| Prior chemotherapy cycles | 0.298 | 0.321 | ||||||
| ≤6 | reference | reference | ||||||
| >6 | 0.467(0.111-1.958) | 0.471(0.107-2.081) | ||||||
| Largest tumor size (cm) | 0.140 | 0.264 | ||||||
| ≤3 | reference | reference | ||||||
| >3 | 1.610(1.030-2.539) | 3.393(1.616-7.125) | ||||||
| CA199 (U/ml) | 0.556 | 0.459 | ||||||
| >200 | 1.189(0.668-2.118) | 1.628(0.692-3.976) | ||||||
| ≤200 | reference | reference | ||||||
| Extrahepatic metastases | 0.817 | 0.702 | ||||||
| Yes | 1.082(0.557-2.098) | 1.238(0.339-2.072) | ||||||
| No | reference | reference | ||||||
| Ascites | 0.522 | 0.624 | ||||||
| Yes | 1.305(0.577-2.953) | 1.318(0.437-3.976) | ||||||
| No | reference | reference | ||||||
| ECOG PS | 0.851 | 0.553 | ||||||
| 0-1 | reference | reference | ||||||
| 1-2 | 1.060(0.577-1.946) | 1.274(0.333-1.802) | ||||||
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; TNM, tumor node metastasis; CA199, carbohydrate antigen 199; PSM, propensity-matched; HAIC, hepatic artery infusion chemotherapy.
The bold values denote statistical significance at P<0.05 level.